Literature DB >> 3007170

Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions.

P C Contreras, K C Rice, A E Jacobson, T L O'Donohue.   

Abstract

The interaction of phencyclidine, dexoxadrol, their analogs and stereoisomers with phencyclidine receptors was compared to their ability to induce stereotyped behavior and ataxia after i.c.v. administration to rats. The order of potency for binding to phencyclidine receptors revealed that among the stereoisomers of phencyclidine derivatives, the (+) isomer was more potent than the (-) isomer. A similar order of potency of phencyclidine derivatives and degree of stereoselectivity was seen in the assays for stereotyped behavior and phencyclidine receptor interactions, which resulted in a good correlation between the relative potencies for binding to phencyclidine receptors and inducing stereotyped behavior. However, the order of potency for induction of ataxia and the stereoselectivity was different than that seen in the assays for phencyclidine receptor interactions and stereotyped behavior. A comparison of relative potencies for binding to phencyclidine receptors to induction of ataxia still resulted in a good fit to a straight line, but the line did not intersect the origin, indicating that a non-phencyclidine receptor component is also involved in mediating ataxia. Dextrorphan and 2-methyl-3,3-diphenyl-3-propylamine were equipotent as phencyclidine in phencyclidine receptor and behavioral assays. The order of potency for interacting with phencyclidine receptors and inducing phencyclidine-like behavior by the isomers of cyclazocine were opposite to that of other phencyclidine analogs. Also, the order of potency for induction of ataxia by the isomers of N-allylnormetazocine was opposite to that for phencyclidine receptor interactions. Ethylketocyclazocine did not induce any stereotyped behavior or ataxia, indicating that it is unlikely that a kappa opioid receptor interaction plays a role in mediating ataxia. Furthermore, stereotyped behavior and ataxia were not due to interactions with mu, kappa or delta opioid receptors as naloxone did not antagonize the behavioral effects of phencyclidine, (-)cyclazocine or (-)N-allylnormetazocine. These results indicate that stereotyped behavior is mediated by phencyclidine receptors, whereas ataxia is mediated by more than just phencyclidine receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007170     DOI: 10.1016/0014-2999(86)90386-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats.

Authors:  D C Hoffman
Journal:  J Neural Transm Gen Sect       Date:  1992

2.  Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor.

Authors:  C B Tyler; J M Bidlack
Journal:  Neurochem Res       Date:  1988-08       Impact factor: 3.996

3.  Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations.

Authors:  P Saransaari; S M Lillrank; S S Oja
Journal:  J Neural Transm Gen Sect       Date:  1993

4.  Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia.

Authors:  Y Noda; K Yamada; H Furukawa; T Nabeshima
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

Review 5.  Phencyclidine. Physiological actions, interactions with excitatory amino acids and endogenous ligands.

Authors:  P C Contreras; J B Monahan; T H Lanthorn; L M Pullan; D A DiMaggio; G E Handelmann; N M Gray; T L O'Donohue
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

Review 6.  The drugs don't work-or do they? Pharmacological and transgenic studies of the contribution of NMDA and GluR-A-containing AMPA receptors to hippocampal-dependent memory.

Authors:  D M Bannerman; J N P Rawlins; M A Good
Journal:  Psychopharmacology (Berl)       Date:  2006-05-05       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.